home > ict > spring 2021 > biopharma sector stands ready to meet demand for innovation
International Clinical Trials

Biopharma Sector Stands Ready to Meet Demand for Innovation

While the ongoing COVID-19 pandemic may not fundamentally alter existing market trends, it will undoubtedly magnify and accelerate them – whether in regard to remote working, e-commerce, and process digitalisation, or to the rise of the biopharma industry.

At first a frightening nightmare, with the rapid spread of the virus globally accompanied by significant morbidity and mortality, the COVID-19 pandemic quickly inspired great hope – through the unprecedented mobilisation of healthcare systems, including the regulatory authorities. From initial identification of the virus, it took only a matter of weeks for the sequencing and the expression of the SARS-CoV-2 spike gene, just 10 months to develop the first vaccines, and today, more than a year since the first COVID-19 case was reported in China, over 560 million doses have been administered in 152 countries and territories (at time of writing). Now, several different vaccines have been developed at record speed, thanks to years of research into related viruses, technology platforms, and billions of dollars in investment. But the pandemic has also exposed some broader challenges and gaps in global capability, and the biopharma sector is both suffering the consequences and in a position to be a potential solution.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Ahmed Bouzidi is Vice President of Biotech Strategic Development at ProductLife Group (PLG). He has been at the forefront of the biopharma industry for more than 30 years, in three continents. He is a Senior Associate of the Royal Society of Medicines, and, previously, has been President of the European Biopharmaceutical Enterprises, and a board member of Vaccines Europe.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

LONDON, UK, 17 June 2022 – Otsuka Pharmaceutical Europe Ltd. (“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for aripiprazole as a 2-month ready-to-use (RTU) long-acting injectable (LAI) for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement